---
title: "Taltz (ixekizumab) in plaque psoriasis: Pharmacology questions"
description: "Pharmacology questions on Taltz (ixekizumab) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pharmacokinetics. Questions: What is the half-life of Taltz? How quickly does Taltz reach peak and steady-state levels? Does the Taltz injection site affect how much drug is absorbed? 3 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/pharmacology"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Taltz (ixekizumab) in plaque psoriasis: Pharmacology questions

Manufacturer: Eli Lilly and Company  
Prescribing information: [Taltz](https://uspl.lilly.com/taltz/taltz.html#pi)

Pharmacology questions that apply to every indication of Taltz are on [Taltz (ixekizumab), all indications: Pharmacology](https://www.evicenter.com/medical-information/taltz/pharmacology).

## Pharmacokinetics

<a id="taltz-half-life"></a>

### What is the half-life of Taltz?

Applies to: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “The mean systemic clearance was 0.39 L/day (37%) and the mean (geometric CV%) half-life was 13 days (40%) in subjects with plaque psoriasis.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=The%20mean%20systemic%20clearance%20was,in%20subjects%20with%20plaque%20psoriasis.)

> “Half-life ~13 days”

Source: [TALTZ: Mechanism of Action | IL-17A & IgG4, captured 2026-11-14](https://taltz.lilly.com/hcp/moa-il17a-igg4#:~:text=Half%2Dlife%20~13%20days)

<a id="taltz-absorption"></a>

### How quickly does Taltz reach peak and steady-state levels?

Applies to: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “Following a single subcutaneous dose of 160 mg in subjects with plaque psoriasis, ixekizumab reached peak mean (±SD) serum concentrations (Cmax) of 16.2 ±6.6 mcg/mL by approximately 4 days post dose.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=Following%20a%20single%20subcutaneous%20dose,approximately%204%20days%20post%20dose.)

> “Steady-state concentrations were achieved by Week 8 following the 160 mg starting dose and 80 mg every 2 weeks dosing regimen; the mean ±SD steady-state trough concentration was 9.3 ±5.3 mcg/mL. Steady-state concentrations were achieved approximately 10 weeks after switching from the 80 mg every 2 weeks dosing regimen to the 80 mg every 4 weeks dosing regimen at Week 12. The mean ±SD steady-state trough concentration was 3.5 ±2.5 mcg/mL.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=Steady%2Dstate%20concentrations%20were%20achieved%20by,concentration%20was%203.5%20%C2%B12.5%20mcg%2FmL.)

<a id="taltz-injection-site-bioavailability"></a>

### Does the Taltz injection site affect how much drug is absorbed?

Applies to: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “In studies of subjects with plaque psoriasis, ixekizumab bioavailability ranged from 60% to 81% following subcutaneous injection. Administration of ixekizumab via injection in the thigh achieved a higher bioavailability relative to that achieved using other injection sites including the arm and abdomen.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=In%20studies%20of%20subjects%20with,including%20the%20arm%20and%20abdomen.)

## Related pages
- [Medical information: Taltz (ixekizumab): Plaque psoriasis](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/guidelines)
